Immune Responses to Neo-Antigens in Patients Treated With Raltegravir: Insights on V(D)J Recombination and RAG-1/2 Recombinase Function.

Trial Profile

Immune Responses to Neo-Antigens in Patients Treated With Raltegravir: Insights on V(D)J Recombination and RAG-1/2 Recombinase Function.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2015

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov
    • 27 Sep 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top